CLINICAL MANIFESTATIONS, CAUSES AND MANAGEMENT STRATEGIES OF PEPTIC ULCER DISEASE
Abstract
Peptic ulcer embraces both gastric and duodenal ulcers and has been a major threat to the world’s population over the past two centuries, with a high morbidity and substantial mortality. Discovery of gastric mucosa infection with Helicobacter pylori (H. pylori) and its association with chronic antral gastritis and peptic ulcer revolutionized the treatment of ulcer illness. H. pylori are causally related to a majority of cases of both duodenal and gastric ulcer, in the west and developing countries. Despite extensive scientific advancements, this disease remains an important clinical setback, largely because of H. pylori infection and widespread use of non-steroidal anti-inflammatory drugs (NSAIDs). Management of peptic ulcer disease generally involves the practice of H2 receptor antagonists, use of proton pump inhibitors, antacids and different H. pylori eradication regimens. This review article outlines the epidemiology, clinical manifestations, diagnosis and treatment strategies of peptic ulcer disease.
Keywords:
management strategies, diagnostic tests, peptic ulcer, Helicobacter pyloriDOI
https://doi.org/10.25004/IJPSDR.2010.02023References
1. Helms RA, Herfindal ET, Quan DJ, Gourley DR. Peptic Ulcer Disease and Gastroesophageal Reflux Disease. In: Text Book of Therapeutics Drug and Disease Management. Edn. 8th, Lippincott Williams and Wilkins Publication, Philadelphia, 2006, pp. 1227-1256.
2. Tortora GJ, Derrickson B. Peptic Ulcer Disease. In: Principles of Anatomy and Physiology. Edn. 11th, Wiley Publication, USA, 2006, pp. 942-943.
3. Boston MA. Peptic ulcer disease. http://knol.google.com/k/peptic-ulcer-disease online publication 7 July 2008. Accessed 15 Oct 2009.
4. Saif SR, Haider M, Niyaz Z, Dr. Abrar, Siddique F. Drugs for Peptic Ulcer. In: Pharmacology Review, Edn. 1st, CBS Publication, New Delhi, 2005, pp. 483-495.
5. Hojgaard L, Nielsen AM, Rune SJ. Peptic ulcer pathophysiology: Acid bicarbonate, and mucosal function. Scand J Gastroenterol.1996; 31(1): 10-15.
6. Garner A, Flemstrom G, Allen A. Gastroduodenal alkaline and mucus secretion. Scand J Gastroenterol. 1983; 18(87): 25-41.
7. Isenberg JI, Flemstrom G. Physiology and pathophysiology of gastroduodenal bicarbonate secretion. Dig Dis. 1991; 23: 27-33.
8. Ainsworth MA, Amelsberg M, Hogan DL, Isenberg JI. Acid/base transport is similar in isolated mammalian duodenal villlus and crypt cells. Gastroenterol. 1994; 106: A37
9. Pal GK, Pal P, Nanda N. Gastric Secretion; Gastric Function Tests; and Pathophysiology of Peptic Ulcer. In: Text Book of Medical Physiology. Edn. 1st, Ahuja Publishing House, New Delhi, 2007, pp. 241-245.
10. Bhattacharya SK, Sen P, Ray A, Das KP. Gastrointestinal Tract. In: Pharmacology. Edn. 2nd, Published by Elsevier India Private limited, New Delhi, 2003, pp. 321-327.
11. Allen A, Pearson JP, Blackburn A, Coan RM, Hutton DA, Mall AS. Pepsins and the mucus barrier in peptic ulcer disease. Scand J Gastroenterol. 1988; 23(1): 50-57.
12. Taylor WH. Biochemistry and pathological physiology of pepsin. Adv Clin Enzymol. 1982; 2: 79-91.
13. Roberts NB, Sheers R, Taylor WH. Pepsin 1 secretion in normal human subjects. Clin Sci. 1981; 61: 37.
14. Kurata JH, Nogawa AN. Meta analysis of risk factors for peptic ulcers: Nonsteroidal anti-inflammatory drugs, Helicobacter pylori and smoking. J Clin Gastroenterol. 1997; 24: 2-17.
15. Bennet PN, Brown MJ. Oesophagus, Stomach and Duodenum. In: Clinical Pharmacology. Edn. 9th, Churchill Livingstone Publication, New Delhi, 2006, pp. 625-632.
16. Baron JH. Peptic ulcer. MT Sinai J Med. 2000; 67 (1): 58-62.
17. Baillie M. The morbid anatomy of some of the most important parts of human body. London. 1793; 85-97.
18. Crampton J. Rupture of the stomach and escape of its contents into the cavity of the abdomen. Med Chir Trans. 1817; 8: 228- 231.
19. Travers B. Additional Observations. Med Chir Trans. 1817; 8: 231-245.
20. Sharma MP, Ahuja V. Current management of acid peptic disorders. J Indian Acad Clin Med. 2003; 4(3): 228-233.
21. Munnangi S, Sonnenberg A. Time trends of Physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Int Med. 1997; 157: 1489-1494.
22. Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol. 1997; 92: 614-620.
23. Barksdale AR, Schwartz RW. The evolving management of gastric outlet obstruction from peptic ulcer disease. Curr Surg. 2002; 59(4): 404-409.
24. Johnson CD, Ellis H. Gastric outlet obstruction now predicts malignancy. Br J Surg. 1990; 77: 1023-1024.
25. Gibson JB, Behrman SW, Fabian TC, Britt LG. Gastric outlet obstruction resulting from peptic ulcer disease requiring surgical intervention is infrequently associated with Helicobacter pylori infection. J Am Coll Surg. 2000; 191: 32-37.
26. Shrestha S, Lau D. Gastric ulcers. http://emedicine.medscape.com/article/ 175765-overview Accessed 12 Oct 2009.
27. Calam J. Clinical science of Helicobacter pylori infection: Ulcers and NSAIDs. Br Med Bull. 1998; 54(1): 55-62.
28. Rang HP, Dale MM, Ritter JM, Moore PK. Diseases of the Stomach and Duodenum. In: Pharmacology. Edn. 5th, Churchill Livingstone Publication, Philadelphia, 2003, pp. 368-372.
29. Richardson CT. Role of aggressive factors in the pathogenesis of peptic ulcer disease. Scand J Gastroenterol. 1990; 25(1): 37- 43.
30. Satoskar RS, Bhandarkar SD, Ainapure SS. Pharmacotherapy of Peptic Ulcer Disease. In: Pharmacology and Pharmacotherapeutics. Edn. 18th, Popular Prakashan, Mumbai. pp. 601 - 616.
31. Tasman-Jones C. Pathogenesis of peptic ulcer disease and gastritis: Importance of aggressive and cytoprotective factors. Scand J Gastroenterol. 1986; 21(1): 1-5.
32. Lamers CBHW. Hormonal regulation of gastric acid in peptic ulcer disease. Scand J Gastroenterol. 1988; 23(1): 5-10.
33. McGuigan JE, Trudeau WL. Differences in rates of gastrin release in normal persons and patients with duodenal ulcer disease. N Engl J Med. 1973; 288: 64-66.
34. Dore MP, Graham DY. Pathogenesis of duodenal ulcer disease: The rest of the story. Bailliere’s Clin Gastroenterol. 2000; 14(1): 97-107.
35. Marieb EN. Peptic Ulcers. In: Anatomy and Physiology. Edn. 8th, South Asia, 2007, pp. 472-474.
36. Waugh A, Grant A. Diseases of the Stomach. In: Ross and Wilson Anatomy and Physiology in Health and Illness. Edn. 9th, Churchill Livingstone Publication, Spain, 2001, pp. 321-324.
37. Metzger F, Styger S, Sieber C, Fliie MV, Vogelbach P, Harder F. Prevalence of Helicobacter pylori infection in peptic ulcer perforations. Swiss Med Wkly. 2001; 131: 99-103.
38. Lee DH, Park HJ, Song SY, Choi SJLW, Lee YC, Chung JB, Kang JK, Park IS, Lee YH, Kim HK. Evaluation of therapeutic regimens for the treatment of Helicobacter pylori infection. Yonsei Med J. 1996; 37(4): 270-277.
39. Cello JP. Helicobacter pylori and peptic ulcer disease. Am J Roentgeno. 1995; 164: 283 – 286.
40. Thagard P. Ulcers and bacteria I: Discovery and acceptance. Stud Hist Phil Biol Biomed Sci. 1998; 29(1): 107-136.
41. O’connor HJ. The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol. 1994; 29(1): 11-15.
42. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995; 2: 33-39.
43. Enaganti S. Peptic ulcer disease - the disease and non drug treatment. Hosp Pharm. 2006; 13: 239-243.
44. Kawakami E, Machado RS, Fonseca JA, Patricio FRS. Clinical and histological features of duodenal ulcer in children and adolescents. J de Pediatr. 2004; 80(4): 321-325.
45. Peura DA. Helicobacter pylori and ulcerogenesis. Am J Med. 1996; 100(5): 19-26.
46. Covacci A, Censini S, Bugnoli M. Molecular characterization of the cag A gene of Helicobacter pylori. Acta Gastroenterol. 1935; 5: 51.
47. Lee A. Future research in peptic ulcer disease. Scand J Gastroenterol. 1994; 29(1): 51-58.
48. Voutilainen M, Mantynen T, Farkkila M, Juhola M, Sipponen P. Impact of nonsteroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. Scand J Gastroenterol. 2001; 36(8): 817-821.
49. Cryer B. Non steroidal anti-inflammatory drug injury. In: Feldman M, Friedman LS, Sleisenger MH. Sleisenger and Fordtran’s gastrointestinal and liver disease: Pathophysioloy/diagnosis/management. Edn. 7th, Philadelphia, 2002, pp. 408-426.
50. Schwartz surgery. Peptic ulcer disease. http://www.ptolemy.ca/members/archives /2007/ulcer/docs/dempsey.pdf Accessed 13 Oct 2009.
51. Malchow-moller A. Treatment of peptic ulcer induced by non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 1987; 22(1): 87-91.
52. Lu H, Graham DY. New development in the mechanistic understanding of peptic ulcer disease. Drug discov today. 2006; 3(4): 431-437.
53. Blum AL. Helicobacter pylori and peptic ulcer disease. Scand J Gastroenterol. 1996; 31(1): 24-27.
54. Ostensen H, Gudmundsen TE, Ostensen M, Burthol PG, Bonnevie O. Smoking, alcohol, coffee, and familial factors: Any association with peptic ulcer disease?: A clinically and radiologically prospective study. Scand J Gastroenterol. 1985; 20(10): 1227-1235.
55. Lam SK, Lee NW, Koo J, Hui WM, Fok KH, Ng M. Randomized crossover trial of cimetidine for duodenal ulcers resistant to standard dose of cimetidine. Gut. 1984; 25: 703-706.
56. Han KS. The effect of an integrated stress management program on the psychologic and physiologic stress reactions of peptic ulcer in Korea. Int J Nurs Stud. 2002; 39: 539-548.
57. Leventein S. Stress and peptic ulcer: life beyond Helicobacter. Br Med J. 1998; 316: 538-541.
58. Bleich A, Ratan Y. Possible relationship between psychological stress and bleeding erosive upper gastrointestinal lesions. Harefuah. 1996; 131: 7-9.
59. Sullivan RM, Gratton A. Lateralized effects of medical prefrontal cortex lesions on neuroendocrine and autonomic stress responses in rats. J Neurosci. 1999; 19: 2834-2840.
60. Peptic ulcer causes http://www.umm.edu/patiented/articles/what_causes_peptic_ulcers _000019_2.htm Accessed Nov 3 2009.
61. Glise H. Epidemiology in peptic ulcer disease: Current status and future aspects. Scand J Gastroenterol. 1990; 25(1): 13-18.
62. Hollender D, Tarnawsky A. Dietary essential fatty acids and the decline in peptic ulcer disease-a hypothesis. Gut. 1986; 27: 239-242.
63. Jayaraj AP, Rees KR, Tovey FI, White JS. A molecular basis of peptic ulceration due to diet. Br J Exp Pathol. 1986; 67: 149-155.
64. Sonnenberg A. Dietary salt and gastric ulcer. Gut. 1986; 27: 1138-1142.
65. Rydning A, Berstad A, Aadland E, Odegard B. Prophylactic effect of dietary fibre in duodenal ulcer disease. Lancet. 1982; 2: 736-739.
66. Kumar N, Kumar A, Broor SL, Vi JC, Anand BS. Effect of milk on patients with duodenal ulcers. Br Med J. 1986; 29(3): 666.
67. Rydning A, Berstad A. Dietary aspects of peptic ulcer disease. Scand J Gastroenterol. 1985; 20(1): 29-33.
68. Malhotra SL. A comparison of unrefined wheat and rice diets in the management of duodenal ulcer. Postgrad Med J. 1978; 54: 6-9.
69. Moynihan BGA. On duodenal ulcer: With notes of 52 operations. Lancet. 1905; 1: 340-346.
70. Gibioki K. A review of seasonal periodicity in peptic ulcer disease. Chronobiol Int. 1987; 4(1): 91-99.
71. Peptic ulcer: http://www.nlm.nih.gov/medlineplus/ency/article/000206.htm Accessed Oct 12 2009.
72. Peptic ulcer disease. http://www.fhcsandpoint.com/pdfs/PEPULCER.pdf Accessed 21 Oct 2009.
73. Peptic ulcer disease. http://www.mgh.org/education/health/ulcer.pdf Accessed 23 Oct 2009.
74. Le TH, Fantry GT. Peptic ulcer disease: eMedicine Gastroenterology. http:// emedicine.medscape.com/article/181753-overview Accessed 19 Oct 2009.
75. Nawaz M, Jehanzaib M, Khan K, Zari M. Role of barium meal examination in diagnosis of peptic ulcer. J Ayub Med Coll. 2008; 20(4): 59-61.
76. Jacobs JM, Hill MC, Steinberg WM. Peptic ulcer disease: CT Evaluation. Radiol. 1991; 178: 745-748.
77. Moller MH, Adamsen S, Wojdemann M, Moller AN. Perforated peptic ulcer: How to improve outcome? Scand J Gastroenterol. 2009; 44(1): 15-22.
78. Ryan PM, George AD, Frank R. Peptic ulcer disease: Clinically relevant causes and treatment. Orthopedics. 2009; 32: 104-107.
79. Mou SM. The relationship between Helicobacter infection and peptic ulcer disease. J Am Med Assoc. 1998; 5(5): 229-232.
80. Graham DY. Diagnosis of Helicobacter pylori infection. Helicobacter. 2006; 11(1): 6-13.
81. Atherton JC, Blaster MJ. Co adaptation of Helicobacter pylori and humans: Ancient history, modern implications. J Clin Invest. 2009; 119(9): 2475-2487.
82. Wood AJJ. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333: 984-991.
83. Kavanagh KT. http://www.mssurg.net/Team5Conferences/Peptic%20Ulcer%20Disease. pdf Accessed on 10 Nov 2009.
84. Falk GW. Current status of Helicobacter pylori in peptic ulcer disease. Clev Clin J med. 1995; 62: 95-104.
85. Cohen JC. Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Gastroenterol. 1995; 3: 289-300.
86. Boon AN, Colledge RN, Walker BR, Hunter JAA. Diseases of Stomach and Duodenum. In: Davidson’s Principle and Practice of Medicine. Edn. 20th, Churchill Livingstone, British Library, 2006, pp. 885-891.
87. Boonpongmanee S, Fleischer DE, Pezzullo JC, Collier K, Mayoral W, AL- Kawas F, Chutkan R, Lewis JH, Tio TL, Benjamin SB. The frequency of peptic ulcer as a cause of upper-GI bleeding is exaggerated. Gastrointest Endosc. 2004; 59(7): 788-794.
88. Gilbert DA. Epidemiology of upper gastrointestinal bleeding. Gastrointest Endosc. 1990; 36(5): S8-S13.
89. Malfertheiner P, Chan F KL, McColl K EL. Peptic ulcer disease. Lancet. 2009; 374: 1449-1461.
90. Passaro E, JR. Peptic ulcer disease. http://web.squ.edu.om/med-Lib/MED_CD/E_ CDs/Surgery/CHAPTERS/CH18.PDF Accessed 21 Oct 2009.
91. McCarthy MD. Management of bleeding peptic ulcer: Current status of intravenous proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2004; 18(5): 7-12.
92. Gisbert JP, Pajares JM. Helicobacter pylori infection and gastric outlet obstruction- prevalence of the infection and role of antimicrobial treatment. Aliment Pharmacol Ther. 2002; 16: 1203-1208.
93. Taskin V, Gurer I, Ozyilkan E, Sare M, Hilmioglu F. Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with gastric outlet obstruction. Helicobacter. 2000; 5: 38-40.
94. Svanes C, Lie SA, Lie RR, Soreide O, Svanes K. Causes of death in patients with peptic ulcer perforation: A long-term follow-up study. Scand. J. Gastroenterol. 1999; 34(1): 18-24.
95. Barksdale AR, Schwartz RW. Current management of perforated peptic ulcer. Curr. Surg. 2000; 57(6): 594-599.
96. Drug treatment of gastric acidity: Gastritis and peptic ulcer disease. http://www. merck.com/mmpe/sec02/ch013/ch013f.html Accessed 20 Oct 2009.
97. Bardhan KD, Nayyar AK, Royston C. History in our lifetime: The changing nature of refractory duodenal ulcer in the era of Histamine- H2 receptor antagonists. Digest liver dis. 2003; 35: 529-536.
98. Tripathi KD. Drugs for Peptic Ulcer. In: Essentials of Medical Pharmacology. Edn. 5th, Jaypee Brother Publication, New Delhi, 2003, pp. 587-598.
99. Penston JG, Wormsley KG. Maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther. 1992; 6: 3-29.
100. Co Q, Sadowski- Hayes LM, Regal RE. Prevalent prescribing of proton pump inhibitors: prudent or Prenicious. Pharm Ther. 2006; 31 (3): 159-167.
101. Brunton LL, Lazo JS, Parker KL. Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease. In: Goodman and Gilman’s Pharmacological Basis of Therapeutics. Edn 11th, McGraw- Hill Publication, New York, 2005, pp. 967- 981.
102. Bardhan DK, Bishop EA, Polak MJ, Romanska MH, Rowland A, Thompson M, Morris P, Schaefer- Preuss S, Luehmann R, McCaldin B. Pentoprazole in severe acid Peptic disease: The effectiveness and safety of 5 years continuous treatment. Digest Liver Dis. 2005; 37: 10-22.
103. Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome Gastroenterol. 2000; 118: S9-S31.
104. Lauristen K, Rask-Madsen J. Prostaglandins and clinical experience in peptic ulcer disease. Scand J Gastroenterol. 1986; 21(1): 174-188.
105. Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: Are they important in its function, disease, or treatment. Gastroenterol. 1985; 89: 1162 – 1188.
106. William JK. Gastrointestinal Drugs. In: Lippincott William and Wilkins. Pharmacology A 2- in Reference for Nurses. 2005, pp. 235-245.
107. Connell AM, Loane RA, In: Robson JM, Sullivan FM, A symposium on carbenoxolone sodium. Butterworths. London. 1968; 25-31.
108. Bank S, Marks IN, Palmer PES, Groll A, Eldik E. A trial of carbenoxolone sodium in the treatment of gastric ulceration. S Afr Med J. 1967; 41: 297-300.
109. Koelz RH. Protective drugs in the treatment of gastroduodenal ulcer disease. Scand J Gastroenterol. 1986; 21(1): 156-164.
110. Emas S. Medical principles for treatment of peptic ulcer. Scand J Gastroenterol. 1987; 22(1): 28-32.
111. H. pylori and peptic ulcer. National Digestive Disease Information Clearinghouse. http://digestive.niddk.nih.gov/ddiseases/pubs/hpylori Accessed 25 Oct 2009.
112. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc. 1994; 272: 65-69.
113. Woodward M, Bird M, Mckernin S, Lourens H, Saunders R. Management of peptic ulcer disease in older people. Aust J Hosp Pharm. 1999; 29(1): 45-50.
114. Leung WK, Sung JJY. Update on medical treatment for peptic ulcer disease. Hong Kong Pract. 1996; 16: 230-232.
115. Suarez MS, Cansino JG, Ilizadale CV, Sabatier CA, Hernandez JC. Three treatment schemes with colloidal bismuth subcitrate (Q-ULCER) in peptic ulcer with Helicobacter pylori. Arch Med Res. 1999; 30: 55-59.
116. Bynum TE. Non-acid mechanisms of gastric and duodenal formation. J Clin Gastroenterol. 1991; 13(2): 56-64.
117. Fowler SF, Khoubian JF, Mathiasen RA, Margulies DR. Peptic ulcer in the elderly is a surgical disease. Am J Surg. 2001; 182: 733-737.
118. Leivonen M, Kivilaakso E. Peptic ulcer bleeding today: Risk factors and characteristics of the disease. Scand J Gastroenterol. 1991; 26(10): 1013-1019.
2. Tortora GJ, Derrickson B. Peptic Ulcer Disease. In: Principles of Anatomy and Physiology. Edn. 11th, Wiley Publication, USA, 2006, pp. 942-943.
3. Boston MA. Peptic ulcer disease. http://knol.google.com/k/peptic-ulcer-disease online publication 7 July 2008. Accessed 15 Oct 2009.
4. Saif SR, Haider M, Niyaz Z, Dr. Abrar, Siddique F. Drugs for Peptic Ulcer. In: Pharmacology Review, Edn. 1st, CBS Publication, New Delhi, 2005, pp. 483-495.
5. Hojgaard L, Nielsen AM, Rune SJ. Peptic ulcer pathophysiology: Acid bicarbonate, and mucosal function. Scand J Gastroenterol.1996; 31(1): 10-15.
6. Garner A, Flemstrom G, Allen A. Gastroduodenal alkaline and mucus secretion. Scand J Gastroenterol. 1983; 18(87): 25-41.
7. Isenberg JI, Flemstrom G. Physiology and pathophysiology of gastroduodenal bicarbonate secretion. Dig Dis. 1991; 23: 27-33.
8. Ainsworth MA, Amelsberg M, Hogan DL, Isenberg JI. Acid/base transport is similar in isolated mammalian duodenal villlus and crypt cells. Gastroenterol. 1994; 106: A37
9. Pal GK, Pal P, Nanda N. Gastric Secretion; Gastric Function Tests; and Pathophysiology of Peptic Ulcer. In: Text Book of Medical Physiology. Edn. 1st, Ahuja Publishing House, New Delhi, 2007, pp. 241-245.
10. Bhattacharya SK, Sen P, Ray A, Das KP. Gastrointestinal Tract. In: Pharmacology. Edn. 2nd, Published by Elsevier India Private limited, New Delhi, 2003, pp. 321-327.
11. Allen A, Pearson JP, Blackburn A, Coan RM, Hutton DA, Mall AS. Pepsins and the mucus barrier in peptic ulcer disease. Scand J Gastroenterol. 1988; 23(1): 50-57.
12. Taylor WH. Biochemistry and pathological physiology of pepsin. Adv Clin Enzymol. 1982; 2: 79-91.
13. Roberts NB, Sheers R, Taylor WH. Pepsin 1 secretion in normal human subjects. Clin Sci. 1981; 61: 37.
14. Kurata JH, Nogawa AN. Meta analysis of risk factors for peptic ulcers: Nonsteroidal anti-inflammatory drugs, Helicobacter pylori and smoking. J Clin Gastroenterol. 1997; 24: 2-17.
15. Bennet PN, Brown MJ. Oesophagus, Stomach and Duodenum. In: Clinical Pharmacology. Edn. 9th, Churchill Livingstone Publication, New Delhi, 2006, pp. 625-632.
16. Baron JH. Peptic ulcer. MT Sinai J Med. 2000; 67 (1): 58-62.
17. Baillie M. The morbid anatomy of some of the most important parts of human body. London. 1793; 85-97.
18. Crampton J. Rupture of the stomach and escape of its contents into the cavity of the abdomen. Med Chir Trans. 1817; 8: 228- 231.
19. Travers B. Additional Observations. Med Chir Trans. 1817; 8: 231-245.
20. Sharma MP, Ahuja V. Current management of acid peptic disorders. J Indian Acad Clin Med. 2003; 4(3): 228-233.
21. Munnangi S, Sonnenberg A. Time trends of Physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Int Med. 1997; 157: 1489-1494.
22. Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol. 1997; 92: 614-620.
23. Barksdale AR, Schwartz RW. The evolving management of gastric outlet obstruction from peptic ulcer disease. Curr Surg. 2002; 59(4): 404-409.
24. Johnson CD, Ellis H. Gastric outlet obstruction now predicts malignancy. Br J Surg. 1990; 77: 1023-1024.
25. Gibson JB, Behrman SW, Fabian TC, Britt LG. Gastric outlet obstruction resulting from peptic ulcer disease requiring surgical intervention is infrequently associated with Helicobacter pylori infection. J Am Coll Surg. 2000; 191: 32-37.
26. Shrestha S, Lau D. Gastric ulcers. http://emedicine.medscape.com/article/ 175765-overview Accessed 12 Oct 2009.
27. Calam J. Clinical science of Helicobacter pylori infection: Ulcers and NSAIDs. Br Med Bull. 1998; 54(1): 55-62.
28. Rang HP, Dale MM, Ritter JM, Moore PK. Diseases of the Stomach and Duodenum. In: Pharmacology. Edn. 5th, Churchill Livingstone Publication, Philadelphia, 2003, pp. 368-372.
29. Richardson CT. Role of aggressive factors in the pathogenesis of peptic ulcer disease. Scand J Gastroenterol. 1990; 25(1): 37- 43.
30. Satoskar RS, Bhandarkar SD, Ainapure SS. Pharmacotherapy of Peptic Ulcer Disease. In: Pharmacology and Pharmacotherapeutics. Edn. 18th, Popular Prakashan, Mumbai. pp. 601 - 616.
31. Tasman-Jones C. Pathogenesis of peptic ulcer disease and gastritis: Importance of aggressive and cytoprotective factors. Scand J Gastroenterol. 1986; 21(1): 1-5.
32. Lamers CBHW. Hormonal regulation of gastric acid in peptic ulcer disease. Scand J Gastroenterol. 1988; 23(1): 5-10.
33. McGuigan JE, Trudeau WL. Differences in rates of gastrin release in normal persons and patients with duodenal ulcer disease. N Engl J Med. 1973; 288: 64-66.
34. Dore MP, Graham DY. Pathogenesis of duodenal ulcer disease: The rest of the story. Bailliere’s Clin Gastroenterol. 2000; 14(1): 97-107.
35. Marieb EN. Peptic Ulcers. In: Anatomy and Physiology. Edn. 8th, South Asia, 2007, pp. 472-474.
36. Waugh A, Grant A. Diseases of the Stomach. In: Ross and Wilson Anatomy and Physiology in Health and Illness. Edn. 9th, Churchill Livingstone Publication, Spain, 2001, pp. 321-324.
37. Metzger F, Styger S, Sieber C, Fliie MV, Vogelbach P, Harder F. Prevalence of Helicobacter pylori infection in peptic ulcer perforations. Swiss Med Wkly. 2001; 131: 99-103.
38. Lee DH, Park HJ, Song SY, Choi SJLW, Lee YC, Chung JB, Kang JK, Park IS, Lee YH, Kim HK. Evaluation of therapeutic regimens for the treatment of Helicobacter pylori infection. Yonsei Med J. 1996; 37(4): 270-277.
39. Cello JP. Helicobacter pylori and peptic ulcer disease. Am J Roentgeno. 1995; 164: 283 – 286.
40. Thagard P. Ulcers and bacteria I: Discovery and acceptance. Stud Hist Phil Biol Biomed Sci. 1998; 29(1): 107-136.
41. O’connor HJ. The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol. 1994; 29(1): 11-15.
42. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995; 2: 33-39.
43. Enaganti S. Peptic ulcer disease - the disease and non drug treatment. Hosp Pharm. 2006; 13: 239-243.
44. Kawakami E, Machado RS, Fonseca JA, Patricio FRS. Clinical and histological features of duodenal ulcer in children and adolescents. J de Pediatr. 2004; 80(4): 321-325.
45. Peura DA. Helicobacter pylori and ulcerogenesis. Am J Med. 1996; 100(5): 19-26.
46. Covacci A, Censini S, Bugnoli M. Molecular characterization of the cag A gene of Helicobacter pylori. Acta Gastroenterol. 1935; 5: 51.
47. Lee A. Future research in peptic ulcer disease. Scand J Gastroenterol. 1994; 29(1): 51-58.
48. Voutilainen M, Mantynen T, Farkkila M, Juhola M, Sipponen P. Impact of nonsteroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. Scand J Gastroenterol. 2001; 36(8): 817-821.
49. Cryer B. Non steroidal anti-inflammatory drug injury. In: Feldman M, Friedman LS, Sleisenger MH. Sleisenger and Fordtran’s gastrointestinal and liver disease: Pathophysioloy/diagnosis/management. Edn. 7th, Philadelphia, 2002, pp. 408-426.
50. Schwartz surgery. Peptic ulcer disease. http://www.ptolemy.ca/members/archives /2007/ulcer/docs/dempsey.pdf Accessed 13 Oct 2009.
51. Malchow-moller A. Treatment of peptic ulcer induced by non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 1987; 22(1): 87-91.
52. Lu H, Graham DY. New development in the mechanistic understanding of peptic ulcer disease. Drug discov today. 2006; 3(4): 431-437.
53. Blum AL. Helicobacter pylori and peptic ulcer disease. Scand J Gastroenterol. 1996; 31(1): 24-27.
54. Ostensen H, Gudmundsen TE, Ostensen M, Burthol PG, Bonnevie O. Smoking, alcohol, coffee, and familial factors: Any association with peptic ulcer disease?: A clinically and radiologically prospective study. Scand J Gastroenterol. 1985; 20(10): 1227-1235.
55. Lam SK, Lee NW, Koo J, Hui WM, Fok KH, Ng M. Randomized crossover trial of cimetidine for duodenal ulcers resistant to standard dose of cimetidine. Gut. 1984; 25: 703-706.
56. Han KS. The effect of an integrated stress management program on the psychologic and physiologic stress reactions of peptic ulcer in Korea. Int J Nurs Stud. 2002; 39: 539-548.
57. Leventein S. Stress and peptic ulcer: life beyond Helicobacter. Br Med J. 1998; 316: 538-541.
58. Bleich A, Ratan Y. Possible relationship between psychological stress and bleeding erosive upper gastrointestinal lesions. Harefuah. 1996; 131: 7-9.
59. Sullivan RM, Gratton A. Lateralized effects of medical prefrontal cortex lesions on neuroendocrine and autonomic stress responses in rats. J Neurosci. 1999; 19: 2834-2840.
60. Peptic ulcer causes http://www.umm.edu/patiented/articles/what_causes_peptic_ulcers _000019_2.htm Accessed Nov 3 2009.
61. Glise H. Epidemiology in peptic ulcer disease: Current status and future aspects. Scand J Gastroenterol. 1990; 25(1): 13-18.
62. Hollender D, Tarnawsky A. Dietary essential fatty acids and the decline in peptic ulcer disease-a hypothesis. Gut. 1986; 27: 239-242.
63. Jayaraj AP, Rees KR, Tovey FI, White JS. A molecular basis of peptic ulceration due to diet. Br J Exp Pathol. 1986; 67: 149-155.
64. Sonnenberg A. Dietary salt and gastric ulcer. Gut. 1986; 27: 1138-1142.
65. Rydning A, Berstad A, Aadland E, Odegard B. Prophylactic effect of dietary fibre in duodenal ulcer disease. Lancet. 1982; 2: 736-739.
66. Kumar N, Kumar A, Broor SL, Vi JC, Anand BS. Effect of milk on patients with duodenal ulcers. Br Med J. 1986; 29(3): 666.
67. Rydning A, Berstad A. Dietary aspects of peptic ulcer disease. Scand J Gastroenterol. 1985; 20(1): 29-33.
68. Malhotra SL. A comparison of unrefined wheat and rice diets in the management of duodenal ulcer. Postgrad Med J. 1978; 54: 6-9.
69. Moynihan BGA. On duodenal ulcer: With notes of 52 operations. Lancet. 1905; 1: 340-346.
70. Gibioki K. A review of seasonal periodicity in peptic ulcer disease. Chronobiol Int. 1987; 4(1): 91-99.
71. Peptic ulcer: http://www.nlm.nih.gov/medlineplus/ency/article/000206.htm Accessed Oct 12 2009.
72. Peptic ulcer disease. http://www.fhcsandpoint.com/pdfs/PEPULCER.pdf Accessed 21 Oct 2009.
73. Peptic ulcer disease. http://www.mgh.org/education/health/ulcer.pdf Accessed 23 Oct 2009.
74. Le TH, Fantry GT. Peptic ulcer disease: eMedicine Gastroenterology. http:// emedicine.medscape.com/article/181753-overview Accessed 19 Oct 2009.
75. Nawaz M, Jehanzaib M, Khan K, Zari M. Role of barium meal examination in diagnosis of peptic ulcer. J Ayub Med Coll. 2008; 20(4): 59-61.
76. Jacobs JM, Hill MC, Steinberg WM. Peptic ulcer disease: CT Evaluation. Radiol. 1991; 178: 745-748.
77. Moller MH, Adamsen S, Wojdemann M, Moller AN. Perforated peptic ulcer: How to improve outcome? Scand J Gastroenterol. 2009; 44(1): 15-22.
78. Ryan PM, George AD, Frank R. Peptic ulcer disease: Clinically relevant causes and treatment. Orthopedics. 2009; 32: 104-107.
79. Mou SM. The relationship between Helicobacter infection and peptic ulcer disease. J Am Med Assoc. 1998; 5(5): 229-232.
80. Graham DY. Diagnosis of Helicobacter pylori infection. Helicobacter. 2006; 11(1): 6-13.
81. Atherton JC, Blaster MJ. Co adaptation of Helicobacter pylori and humans: Ancient history, modern implications. J Clin Invest. 2009; 119(9): 2475-2487.
82. Wood AJJ. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333: 984-991.
83. Kavanagh KT. http://www.mssurg.net/Team5Conferences/Peptic%20Ulcer%20Disease. pdf Accessed on 10 Nov 2009.
84. Falk GW. Current status of Helicobacter pylori in peptic ulcer disease. Clev Clin J med. 1995; 62: 95-104.
85. Cohen JC. Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Gastroenterol. 1995; 3: 289-300.
86. Boon AN, Colledge RN, Walker BR, Hunter JAA. Diseases of Stomach and Duodenum. In: Davidson’s Principle and Practice of Medicine. Edn. 20th, Churchill Livingstone, British Library, 2006, pp. 885-891.
87. Boonpongmanee S, Fleischer DE, Pezzullo JC, Collier K, Mayoral W, AL- Kawas F, Chutkan R, Lewis JH, Tio TL, Benjamin SB. The frequency of peptic ulcer as a cause of upper-GI bleeding is exaggerated. Gastrointest Endosc. 2004; 59(7): 788-794.
88. Gilbert DA. Epidemiology of upper gastrointestinal bleeding. Gastrointest Endosc. 1990; 36(5): S8-S13.
89. Malfertheiner P, Chan F KL, McColl K EL. Peptic ulcer disease. Lancet. 2009; 374: 1449-1461.
90. Passaro E, JR. Peptic ulcer disease. http://web.squ.edu.om/med-Lib/MED_CD/E_ CDs/Surgery/CHAPTERS/CH18.PDF Accessed 21 Oct 2009.
91. McCarthy MD. Management of bleeding peptic ulcer: Current status of intravenous proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2004; 18(5): 7-12.
92. Gisbert JP, Pajares JM. Helicobacter pylori infection and gastric outlet obstruction- prevalence of the infection and role of antimicrobial treatment. Aliment Pharmacol Ther. 2002; 16: 1203-1208.
93. Taskin V, Gurer I, Ozyilkan E, Sare M, Hilmioglu F. Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with gastric outlet obstruction. Helicobacter. 2000; 5: 38-40.
94. Svanes C, Lie SA, Lie RR, Soreide O, Svanes K. Causes of death in patients with peptic ulcer perforation: A long-term follow-up study. Scand. J. Gastroenterol. 1999; 34(1): 18-24.
95. Barksdale AR, Schwartz RW. Current management of perforated peptic ulcer. Curr. Surg. 2000; 57(6): 594-599.
96. Drug treatment of gastric acidity: Gastritis and peptic ulcer disease. http://www. merck.com/mmpe/sec02/ch013/ch013f.html Accessed 20 Oct 2009.
97. Bardhan KD, Nayyar AK, Royston C. History in our lifetime: The changing nature of refractory duodenal ulcer in the era of Histamine- H2 receptor antagonists. Digest liver dis. 2003; 35: 529-536.
98. Tripathi KD. Drugs for Peptic Ulcer. In: Essentials of Medical Pharmacology. Edn. 5th, Jaypee Brother Publication, New Delhi, 2003, pp. 587-598.
99. Penston JG, Wormsley KG. Maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther. 1992; 6: 3-29.
100. Co Q, Sadowski- Hayes LM, Regal RE. Prevalent prescribing of proton pump inhibitors: prudent or Prenicious. Pharm Ther. 2006; 31 (3): 159-167.
101. Brunton LL, Lazo JS, Parker KL. Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease. In: Goodman and Gilman’s Pharmacological Basis of Therapeutics. Edn 11th, McGraw- Hill Publication, New York, 2005, pp. 967- 981.
102. Bardhan DK, Bishop EA, Polak MJ, Romanska MH, Rowland A, Thompson M, Morris P, Schaefer- Preuss S, Luehmann R, McCaldin B. Pentoprazole in severe acid Peptic disease: The effectiveness and safety of 5 years continuous treatment. Digest Liver Dis. 2005; 37: 10-22.
103. Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome Gastroenterol. 2000; 118: S9-S31.
104. Lauristen K, Rask-Madsen J. Prostaglandins and clinical experience in peptic ulcer disease. Scand J Gastroenterol. 1986; 21(1): 174-188.
105. Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: Are they important in its function, disease, or treatment. Gastroenterol. 1985; 89: 1162 – 1188.
106. William JK. Gastrointestinal Drugs. In: Lippincott William and Wilkins. Pharmacology A 2- in Reference for Nurses. 2005, pp. 235-245.
107. Connell AM, Loane RA, In: Robson JM, Sullivan FM, A symposium on carbenoxolone sodium. Butterworths. London. 1968; 25-31.
108. Bank S, Marks IN, Palmer PES, Groll A, Eldik E. A trial of carbenoxolone sodium in the treatment of gastric ulceration. S Afr Med J. 1967; 41: 297-300.
109. Koelz RH. Protective drugs in the treatment of gastroduodenal ulcer disease. Scand J Gastroenterol. 1986; 21(1): 156-164.
110. Emas S. Medical principles for treatment of peptic ulcer. Scand J Gastroenterol. 1987; 22(1): 28-32.
111. H. pylori and peptic ulcer. National Digestive Disease Information Clearinghouse. http://digestive.niddk.nih.gov/ddiseases/pubs/hpylori Accessed 25 Oct 2009.
112. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc. 1994; 272: 65-69.
113. Woodward M, Bird M, Mckernin S, Lourens H, Saunders R. Management of peptic ulcer disease in older people. Aust J Hosp Pharm. 1999; 29(1): 45-50.
114. Leung WK, Sung JJY. Update on medical treatment for peptic ulcer disease. Hong Kong Pract. 1996; 16: 230-232.
115. Suarez MS, Cansino JG, Ilizadale CV, Sabatier CA, Hernandez JC. Three treatment schemes with colloidal bismuth subcitrate (Q-ULCER) in peptic ulcer with Helicobacter pylori. Arch Med Res. 1999; 30: 55-59.
116. Bynum TE. Non-acid mechanisms of gastric and duodenal formation. J Clin Gastroenterol. 1991; 13(2): 56-64.
117. Fowler SF, Khoubian JF, Mathiasen RA, Margulies DR. Peptic ulcer in the elderly is a surgical disease. Am J Surg. 2001; 182: 733-737.
118. Leivonen M, Kivilaakso E. Peptic ulcer bleeding today: Risk factors and characteristics of the disease. Scand J Gastroenterol. 1991; 26(10): 1013-1019.
Published
01-04-2010
Statistics
Abstract Display: 589 
PDF Downloads: 522
Dimension Badge
How to Cite
“CLINICAL MANIFESTATIONS, CAUSES AND MANAGEMENT STRATEGIES OF PEPTIC ULCER DISEASE”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 2, no. 2, Apr. 2010, pp. 99-106, https://doi.org/10.25004/IJPSDR.2010.02023.
Issue
Section
Review Article
Copyright (c) 2010 Rakesh Pahwa, Neeta ., Vipin Kumar, Kanchan Kohli
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
“CLINICAL MANIFESTATIONS, CAUSES AND MANAGEMENT STRATEGIES OF PEPTIC ULCER DISEASE”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 2, no. 2, Apr. 2010, pp. 99-106, https://doi.org/10.25004/IJPSDR.2010.02023.
